Zummo Jacqueline
Chief R&D Officer
Zummo Jacqueline has filed 5 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2026. 5 of those filings fall inside the rolling window. Most recent filing: Apr 9, 2026.
On the most recent filing, Zummo Jacqueline is listed as Chief R&D Officer at Protara Therapeutics, Inc. Inside the rolling window, Zummo Jacqueline reported no open-market purchases and 2 open-market sales totaling $125K in TARA. The largest disclosed transaction in the window is a sale of 22,598 TARA shares on Apr 1, 2026, worth $119K.
Companies traded
Other insiders at TARA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$125K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Zummo Jacqueline made?
Zummo Jacqueline has filed 5 SEC Form 4 filings (5 transaction rows) across 1 company since 2026.
Which companies does Zummo Jacqueline trade?
Zummo Jacqueline has filed SEC Form 4 disclosures for 1 company, including TARA.
When was Zummo Jacqueline's most recent SEC Form 4 filing?
Zummo Jacqueline's most recent SEC Form 4 filing on Tracefour is dated Apr 9, 2026.
What is Zummo Jacqueline's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Zummo Jacqueline is listed as Chief R&D Officer.
What is Zummo Jacqueline's total buy and sell value in the current window?
Inside the rolling retention window, Zummo Jacqueline bought $0 and sold $125K based on SEC Form 4 filings.
What was Zummo Jacqueline's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 22,598 TARA shares on 2026-04-01, worth $119K, per SEC Form 4 filings.